| Literature DB >> 17374753 |
Peter Tomasec1, Eddie C Y Wang2, Veronika Groh3, Thomas Spies3, Brian P McSharry1, Rebecca J Aicheler1, Richard J Stanton1, Gavin W G Wilkinson1.
Abstract
We report that delivery of first-generation replication-deficient adenovirus (RDAd) vectors into primary human fibroblasts is associated with the induction of natural killer (NK) cell-mediated cytolysis in vitro. RDAd vector delivery induced cytolysis by a range of NK cell populations including the NK cell clone NKL, primary polyclonal NK lines and a proportion of NK clones (36 %) in autologous HLA-matched assays. Adenovirus-induced cytolysis was inhibited by antibody blocking of the NK-activating receptor NKG2D, implicating this receptor in this function. NKG2D is ubiquitously expressed on NK cells and CD8(+) T cells. Significantly, gamma-irradiation of the vector eliminated the effect, suggesting that breakthrough expression from the vector induces at least some of the pro-inflammatory responses of unknown aetiology following the application of RDAd vectors during in vivo gene delivery.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17374753 PMCID: PMC2841999 DOI: 10.1099/vir.0.82685-0
Source DB: PubMed Journal: J Gen Virol ISSN: 0022-1317 Impact factor: 3.891
Fig. 1.Induction of NK cell-mediated cytolysis following RDAd infection. (a) Susceptibility of human fibroblasts infected for 72 h with a control vector with no transgene insertion (+RDAd) to cell-mediated cytolysis of polyclonal NK lines; autologous assays, K562 cells and mock-infected fibroblasts were used as cytotoxicity points of reference. (b) Infection of HFFF with RDAd and not with γ-irradiated RDAd induced NKL killing [72 h post-infection (p.i.)]. E : T Ratio, effector : target cell ratio. (c) Susceptibility to NKL cells was not increased by soluble factors (RDAd-medium) secreted from infected cells (72 h p.i.). (d) NKG2D interactions and NKL killing were blocked efficiently with the anti-NKG2D antibody. (e) Similar results were observed using polyclonal NK lines in autologous assays. (f) mRNA levels of multiple NKG2D ligands were enhanced following RDAd infection using semiquantitative RT-PCR.
Susceptibility of RDAd-infected cells to NK cell-mediated lysis
Autologous assays in which values are given as percentage of 51Cr released±sd. E : T Ratio, effector : target cell ratio.
| D8.NKc1C10* | 58 : 1 | 48±2 | 53±3 | − | 63±1 |
| 8 : 1 | 13±2 | 21±1 | − | 32±3 | |
| 27 : 1 | 22±2 | − | 39±1† | 56±4 | |
| D8.NKc1E11* | 21 : 1 | 29±2 | 34±1 | − | 48±4 |
| 40 : 1 | 10±1 | − | 33±4† | 52±3 | |
| 23 : 1 | 24±1 | 18±1 | − | 46±5 | |
| D8.NKc1F11* | 44 : 1 | 24±2 | 38±2† | − | 52±3 |
| 32 : 1 | 7±1 | 19±1† | − | 31±1 | |
| 19 : 1 | 12±1 | − | 23±1† | 35±1 | |
| D8.NKc2F3* | 25 : 1 | 38±3 | 45±2 | − | 49±5 |
| 20 : 1 | 22±1 | − | 31±3 | 37±2 | |
| D8.NKc2G9 | 5 : 1 | 2±1 | 3±1 | − | 23±2 |
| D8.NKc3C8* | 26 : 1 | 8±1 | 12±4 | − | 29±3 |
| 35 : 1 | 4±2 | 24±1† | − | 40±4 | |
| 20 : 1 | 11±2 | − | 21±1† | 46±3 | |
| D8.NKc3D9 | 11 : 1 | 11±1 | 19±3 | − | 34±3 |
| D8.NKc3E9* | 32 : 1 | 35±1 | 31±1 | − | 28±4 |
| 18 : 1 | 7±1 | − | 11±1 | 30±3 | |
| D8.NKc4F3* | 25 : 1 | 48±2 | 40±6 | − | 52±1 |
| 10 : 1 | 24±1 | − | 39±1† | 61±4 | |
| D8.NKc4E10* | 44 : 1 | 13±3 | 26±3† | − | 40±4 |
| 23 : 1 | 11±2 | 30±3† | − | 41±4 | |
| 20 : 1 | 6±1 | − | 16±2† | 30±3 | |
| D8.NKc5E7 | 14 : 1 | 7±3 | 5±3 | − | 19±2 |
| D8.NKc5C11* | 63 : 1 | 36±2 | 43±3 | − | 55±2 |
| 66 : 1 | 19±2 | 36±3† | − | 51±3 | |
| 50 : 1 | 24±3 | − | 34±3† | 59±4 |
*Multiple assays carried out at different times showing stability of clonal response.
†Increase in killing of RDAd-infected cells was greater than 10 %.
Effect of RDAd infection on cytotoxicity mediated by individual NK clones derived from multiple donors
Autologous assays; each event represents results obtained from an individual clone (clones tested more than once were averaged as a single event, some clones were tested against RDAd–GFP, as in Table 1).
| CD94hi clones | |||
| D3 | 3/4 | 0/4 | 1/4 |
| D8‡ | 4/13 | 0/13 | 9/13 |
| D9 | 22/64 | 0/64 | 42/64 |
| Total | 29/81 (36 %) | 0/81 | 52/81 (64 %) |
*Increase or decrease in cytolysis was greater than 10 %.
†Increase or decrease in cytolysis was less than 10 %.
‡Complete results using this donor are presented in Table 1.